These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18258851)

  • 1. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.
    Ninichuk V; Clauss S; Kulkarni O; Schmid H; Segerer S; Radomska E; Eulberg D; Buchner K; Selve N; Klussmann S; Anders HJ
    Am J Pathol; 2008 Mar; 172(3):628-37. PubMed ID: 18258851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease.
    Darisipudi MN; Kulkarni OP; Sayyed SG; Ryu M; Migliorini A; Sagrinati C; Parente E; Vater A; Eulberg D; Klussmann S; Romagnani P; Anders HJ
    Am J Pathol; 2011 Jul; 179(1):116-24. PubMed ID: 21703397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
    Baeck C; Wehr A; Karlmark KR; Heymann F; Vucur M; Gassler N; Huss S; Klussmann S; Eulberg D; Luedde T; Trautwein C; Tacke F
    Gut; 2012 Mar; 61(3):416-26. PubMed ID: 21813474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spiegelmer Inhibition of MCP-1/CCR2--Potential as an Adjunct Immunosuppressive Therapy in Transplantation.
    Kalnins A; Thomas MN; Andrassy M; Müller S; Wagner A; Pratschke S; Rentsch M; Klussmann S; Kauke T; Angele MK; Bazhin AV; Fischereder M; Werner J; Guba M; Andrassy J
    Scand J Immunol; 2015 Aug; 82(2):102-9. PubMed ID: 25970072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy.
    Clauss S; Gross O; Kulkarni O; Avila-Ferrufino A; Radomska E; Segerer S; Eulberg D; Klussmann S; Anders HJ
    J Pathol; 2009 May; 218(1):40-7. PubMed ID: 19156777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice.
    Ninichuk V; Khandoga AG; Segerer S; Loetscher P; Schlapbach A; Revesz L; Feifel R; Khandoga A; Krombach F; Nelson PJ; Schlöndorff D; Anders HJ
    Am J Pathol; 2007 Apr; 170(4):1267-76. PubMed ID: 17392166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice.
    Seok SJ; Lee ES; Kim GT; Hyun M; Lee JH; Chen S; Choi R; Kim HM; Lee EY; Chung CH
    Nephrol Dial Transplant; 2013 Jul; 28(7):1700-10. PubMed ID: 23794669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice.
    Baeck C; Wei X; Bartneck M; Fech V; Heymann F; Gassler N; Hittatiya K; Eulberg D; Luedde T; Trautwein C; Tacke F
    Hepatology; 2014 Mar; 59(3):1060-72. PubMed ID: 24481979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy.
    Ninichuk V; Kulkarni O; Clauss S; Anders H-
    Eur J Med Res; 2007 Aug; 12(8):351-5. PubMed ID: 17933712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL2/MCP-1 and CXCL12/SDF-1 blockade by L-aptamers improve pancreatic islet engraftment and survival in mouse.
    Citro A; Pellegrini S; Dugnani E; Eulberg D; Klussmann S; Piemonti L
    Am J Transplant; 2019 Nov; 19(11):3131-3138. PubMed ID: 31267721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.
    Kulkarni O; Pawar RD; Purschke W; Eulberg D; Selve N; Buchner K; Ninichuk V; Segerer S; Vielhauer V; Klussmann S; Anders HJ
    J Am Soc Nephrol; 2007 Aug; 18(8):2350-8. PubMed ID: 17625118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.
    Sayyed SG; Ryu M; Kulkarni OP; Schmid H; Lichtnekert J; Grüner S; Green L; Mattei P; Hartmann G; Anders HJ
    Kidney Int; 2011 Jul; 80(1):68-78. PubMed ID: 21508925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
    Devarapu SK; Kumar Vr S; Rupanagudi KV; Kulkarni OP; Eulberg D; Klussmann S; Anders HJ
    Clin Immunol; 2016 Aug; 169():139-147. PubMed ID: 27392463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10.
    Sayyed SG; Gaikwad AB; Lichtnekert J; Kulkarni O; Eulberg D; Klussmann S; Tikoo K; Anders HJ
    Nephrol Dial Transplant; 2010 Jun; 25(6):1811-7. PubMed ID: 20067909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats.
    Kikuchi Y; Imakiire T; Yamada M; Saigusa T; Hyodo T; Hyodo N; Suzuki S; Miura S
    Nephrol Dial Transplant; 2005 Aug; 20(8):1573-81. PubMed ID: 15905195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.
    Menne J; Eulberg D; Beyer D; Baumann M; Saudek F; Valkusz Z; Więcek A; Haller H;
    Nephrol Dial Transplant; 2017 Feb; 32(2):307-315. PubMed ID: 28186566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis.
    Wilkening A; Krappe J; Mühe AM; Lindenmeyer MT; Eltrich N; Luckow B; Vielhauer V
    Nephrol Dial Transplant; 2020 Feb; 35(2):227-239. PubMed ID: 30597038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.
    Sayyed SG; Hägele H; Kulkarni OP; Endlich K; Segerer S; Eulberg D; Klussmann S; Anders HJ
    Diabetologia; 2009 Nov; 52(11):2445-54. PubMed ID: 19707743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.
    Chow F; Ozols E; Nikolic-Paterson DJ; Atkins RC; Tesch GH
    Kidney Int; 2004 Jan; 65(1):116-28. PubMed ID: 14675042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.